NO994413L - Kationiske lipidblandinger mÕlsökende angiogene endotelceller - Google Patents

Kationiske lipidblandinger mÕlsökende angiogene endotelceller

Info

Publication number
NO994413L
NO994413L NO994413A NO994413A NO994413L NO 994413 L NO994413 L NO 994413L NO 994413 A NO994413 A NO 994413A NO 994413 A NO994413 A NO 994413A NO 994413 L NO994413 L NO 994413L
Authority
NO
Norway
Prior art keywords
angiogenic endothelial
endothelial cells
cationic lipid
lipid mixtures
targeting angiogenic
Prior art date
Application number
NO994413A
Other languages
English (en)
Other versions
NO327487B1 (no
NO994413D0 (no
Inventor
Donald M Mcdonald
John Mcclean
O Gavin Thurston
Peter Baluk
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO994413D0 publication Critical patent/NO994413D0/no
Publication of NO994413L publication Critical patent/NO994413L/no
Publication of NO327487B1 publication Critical patent/NO327487B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19994413A 1997-03-12 1999-09-10 Kationisk liposom samt anvendelse derav NO327487B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,337 US5837283A (en) 1997-03-12 1997-03-12 Cationic lipid compositions targeting angiogenic endothelial cells
PCT/US1998/004891 WO1998040052A1 (en) 1997-03-12 1998-03-12 Cationic lipid compositions targeting angiogenic endothelial cells

Publications (3)

Publication Number Publication Date
NO994413D0 NO994413D0 (no) 1999-09-10
NO994413L true NO994413L (no) 1999-11-10
NO327487B1 NO327487B1 (no) 2009-07-13

Family

ID=25230519

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994413A NO327487B1 (no) 1997-03-12 1999-09-10 Kationisk liposom samt anvendelse derav

Country Status (13)

Country Link
US (7) US5837283A (no)
EP (2) EP1767192A3 (no)
JP (2) JP4463880B2 (no)
KR (1) KR100530534B1 (no)
AT (1) ATE362753T1 (no)
AU (1) AU727946B2 (no)
BR (1) BR9808018A (no)
CA (1) CA2283327C (no)
DE (1) DE69837807T2 (no)
ES (1) ES2284201T3 (no)
IL (2) IL131697A0 (no)
NO (1) NO327487B1 (no)
WO (1) WO1998040052A1 (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6930094B1 (en) * 1997-05-09 2005-08-16 Merckle Gmbh Tissue factor for influencing blood vessel formation
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6130207A (en) * 1997-11-05 2000-10-10 South Alabama Medical Science Foundation Cell-specific molecule and method for importing DNA into a nucleus
US6082364A (en) * 1997-12-15 2000-07-04 Musculoskeletal Development Enterprises, Llc Pluripotential bone marrow cell line and methods of using the same
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US6225293B1 (en) * 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
ES2296419T3 (es) 1998-11-12 2008-04-16 Invitrogen Corporation Reactivos de transfeccion.
DK1059092T3 (da) * 1999-06-08 2006-03-27 Gentium Spa Anvendelse af komplekser af kationiske liposomer og polydeoxyribonukleotider som medikamenter
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
US6611833B1 (en) * 1999-06-23 2003-08-26 Tissueinformatics, Inc. Methods for profiling and classifying tissue using a database that includes indices representative of a tissue population
EA005923B1 (ru) * 1999-09-09 2005-08-25 Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния Доставка таксанов к ангиогенным кровеносным сосудам с помощью катионных липосом
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
WO2001032222A1 (en) * 1999-11-03 2001-05-10 Mbt Munich Biotechnology Gmbh Selective toxin expression in angiogenic endothelial cells
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20020034537A1 (en) * 2000-05-03 2002-03-21 Brita Schulze Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20020026945A1 (en) * 2000-07-24 2002-03-07 Gomer Charles J. Enhancement of photodynamic therapy by anti-angiogenic treatment
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
AU2002250081A1 (en) * 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
US6627658B2 (en) * 2001-03-02 2003-09-30 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US20030186390A1 (en) * 2001-03-22 2003-10-02 De Jong Gary Methods for delivering nucleic acid molecules into cells and assessment thereof
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US6936469B2 (en) 2001-03-22 2005-08-30 Chromos Molecular Systems Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US20030166593A1 (en) * 2001-04-30 2003-09-04 Kenneth Chien Non-viral vesicle vector for cardiac specific gene delivery
US20050233990A1 (en) * 2001-08-29 2005-10-20 Yong-Serk Park Anti-cancer agents comprising disintegrin genes and the treating methods
AU2002362461A1 (en) * 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
AU2002350245A1 (en) * 2001-11-26 2003-06-10 Exelixis Inc. Mhyps as modifiers of branching morphogenesis and methods of use
US7488313B2 (en) * 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20040267355A1 (en) * 2002-04-30 2004-12-30 Neal Scott Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
AU2003221584A1 (en) * 2002-05-01 2003-11-17 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
EP1513538A4 (en) * 2002-06-14 2007-08-22 Mirus Bio Corp Novel methods for introducing polynucleotides into cells
US20030235565A1 (en) * 2002-06-18 2003-12-25 Cheung Ling Yuk Feed additives for shrimp culture
PT1530465E (pt) * 2002-06-26 2010-01-05 Medigene Ag Processo para produção de uma preparação lipossomal catiónica que compreende um composto lipofílico
US20040034336A1 (en) * 2002-08-08 2004-02-19 Neal Scott Charged liposomes/micelles with encapsulted medical compounds
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20040197319A1 (en) * 2003-03-24 2004-10-07 Paul Harch Wound healing composition derived from low platelet concentration plasma
US7330851B2 (en) * 2003-08-18 2008-02-12 Eaglehawk, Limited Data security through dissembly of data elements or connections between elements
CA2542217C (en) * 2003-10-15 2018-03-27 Medigene Ag Method of administering cationic liposomes comprising an active drug
AU2005251463A1 (en) * 2004-06-14 2005-12-22 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
US20060134066A1 (en) * 2004-12-22 2006-06-22 Peyman Gholam A Localization of vectors and other agents
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
US20090175930A1 (en) * 2006-01-11 2009-07-09 Nobuhiro Yagi Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
WO2007089043A1 (ja) * 2006-02-03 2007-08-09 Takeda Pharmaceutical Company Limited リポソーム製剤
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
PL2631248T3 (pl) 2007-06-15 2018-06-29 Medigene Ag Leczenie nowotworów z użyciem specyficznego przeciwciała anty-L1
PL2222697T3 (pl) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
KR101734955B1 (ko) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 아미노알콜 리피도이드 및 그의 용도
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
BR112015022660A2 (pt) 2013-03-14 2017-10-31 Shire Human Genetic Therapies métodos para a purificação de rna mensageiro
NZ751462A (en) 2013-03-14 2021-07-30 Shire Human Genetic Therapies Cftr mrna compositions and related methods and uses
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
EP3060257B1 (en) 2013-10-22 2021-02-24 Translate Bio, Inc. Lipid formulations for delivery of messenger rna
EP4276176A3 (en) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
MA48050A (fr) 2014-05-30 2020-02-12 Translate Bio Inc Lipides biodégradables pour l'administration d'acides nucléiques
KR102387898B1 (ko) 2014-06-24 2022-04-15 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016050702A1 (en) 2014-09-30 2016-04-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
WO2016081203A2 (en) 2014-11-17 2016-05-26 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
CN117903316A (zh) 2016-07-29 2024-04-19 朱诺治疗学股份有限公司 抗独特型抗体及相关方法
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
EP4192868A1 (en) 2020-08-05 2023-06-14 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5264318A (en) * 1987-06-15 1993-11-23 Sanyo-Kokusaku Pulp Co., Ltd. Positive type photosensitive composition developable with water comprising a photocrosslinking agent, a water-soluble resin and an aqueous synthetic resin
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH0395118A (ja) 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
AU625013B2 (en) * 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0625207A1 (en) * 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
DK0703909T3 (da) * 1993-06-11 2000-09-11 Upjohn Co Delta6,7-taxoler, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
DE69427251T2 (de) 1993-07-27 2001-10-31 Terumo K.K., Tokio/Tokyo Verabreichungssystem für Arzneistoffe
JP3570561B2 (ja) * 1993-07-27 2004-09-29 テルモ株式会社 血管内皮損傷部位を認識する担体
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
MX9605109A (es) * 1994-04-26 1997-08-30 Childrens Medical Center Angiostatina y metodo de uso para la inhibicion de angiogenesis.
US5580898A (en) * 1994-05-24 1996-12-03 The Trustees Of The University Of Pennsylvania Method of stabilizing microtubules
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6126086A (en) * 1995-01-10 2000-10-03 Georgia Tech Research Corp. Oscillating capillary nebulizer with electrospray
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
BR9708701A (pt) 1996-04-17 2000-01-04 Hoechst Marion Roussel De Gmbh Inibidores anti-sense de expressão do fator de crescimento endotelial vascular.
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
EP1342477A1 (en) * 1996-07-16 2003-09-10 Archibald James Mixson, M.D. Cationic vehicle: dna complexes and their use in gene therapy
JP2001502666A (ja) * 1996-09-12 2001-02-27 ジェネメディシン，インコーポレイテッド 肺遺伝子送達のための組成物および方法
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
WO2000047235A2 (en) 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis

Also Published As

Publication number Publication date
CA2283327C (en) 2008-07-15
US5837283A (en) 1998-11-17
IL171355A (en) 2010-12-30
ES2284201T3 (es) 2007-11-01
DE69837807T2 (de) 2007-10-11
JP4463880B2 (ja) 2010-05-19
US20020155102A1 (en) 2002-10-24
JP2007084565A (ja) 2007-04-05
US7094424B2 (en) 2006-08-22
WO1998040052A1 (en) 1998-09-17
EP1014945A4 (en) 2002-10-09
BR9808018A (pt) 2000-03-08
KR100530534B1 (ko) 2005-11-22
EP1767192A3 (en) 2011-05-04
CA2283327A1 (en) 1998-09-17
AU6461398A (en) 1998-09-29
US20040192776A1 (en) 2004-09-30
EP1014945B1 (en) 2007-05-23
US20030077305A1 (en) 2003-04-24
NO327487B1 (no) 2009-07-13
ATE362753T1 (de) 2007-06-15
US6120799A (en) 2000-09-19
AU727946B2 (en) 2001-01-04
EP1767192A2 (en) 2007-03-28
US20040072795A1 (en) 2004-04-15
EP1014945A1 (en) 2000-07-05
DE69837807D1 (de) 2007-07-05
NO994413D0 (no) 1999-09-10
US7494666B2 (en) 2009-02-24
US6756055B2 (en) 2004-06-29
US7135192B2 (en) 2006-11-14
WO1998040052A9 (en) 1999-09-02
IL131697A0 (en) 2001-03-19
US20020197306A1 (en) 2002-12-26
KR20000076182A (ko) 2000-12-26
JP2001509816A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
NO994413L (no) Kationiske lipidblandinger mÕlsökende angiogene endotelceller
EE200200127A (et) Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda
DK0909183T3 (da) DHA-konjugerede farmaceutisk midler
ATE273320T1 (de) Fusogene liposomen
ATE384736T1 (de) Subzelluläres targeting von therapeutischen proteinen
TR199902731T2 (xx) Kimyasal bile�ikler.
ATE359825T1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
DK0880539T3 (da) Nucleosidanaloger
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
IT1283876B1 (it) Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare
IT8619961A0 (it) Supporto per prodotti da cucire per la cucitura della zona di punta di cravatte.
DK0904282T3 (da) Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
DE69130569D1 (de) Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin
IT1292411B1 (it) Supporto per contenitori in generale e valigie ventiquattrore in particolare,adatto per motocicli e simili
ITMI931082A1 (it) Coniugati di farmaci antivirali ad attivita' epatotropica, relativi veicolanti e composizioni farmaceutiche che li contengono
DE50004490D1 (de) Träger-etikett-anordnung
IT236438Y1 (it) Struttura di etichetta adesiva,particolarmente studiata per flaconidi prodotti per l'igiene personale,ad elevata praticita' di impiego

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees